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Abstract: Non-steroidal anti-inﬂ  ammatory agents (NSAIDs) remain the mainstay of treatment 
for ankylosing spondylitis (AS) though one recent trial suggests that continuous as opposed to 
on-demand use may be superior in preventing progression of structural damage. One particular 
NSAID, which is a highly selective cyclo-oxygenase 2 inhibitor, etoricoxib, may be superior 
to standard NSAIDs for AS. Second-line agents typically used for rheumatoid arthritis appear 
to lack efﬁ  cacy. Salazopyrin is only moderately effective in the subgroup of AS patients with 
concomitant peripheral arthritis and not in those with purely axial disease. A recent trial showed 
that there is no greater efﬁ  cacy in patients presenting early in their disease course. Three anti-
tumor necrosis factor alpha agents, inﬂ  iximab, etanercept, and adalimumab, are now available 
for the treatment of AS, the latest being adalimumab. All possess similar clinical efﬁ  cacy in 
phase III trials with response rates of about 60%. Imaging studies using magnetic resonance 
show substantial amelioration of inﬂ  ammatory lesions in the spine and sacroiliac joints. There is 
as yet no evidence that any of these agents prevent progression of structural damage. One study 
that evaluated etanercept demonstrated no impact on damage progression. Increasing evidence 
points to the superiority of the two monoclonal antibodies, inﬂ  iximab and adalimumab, over 
etanercept for the treatment of extra-articular manifestations typically seen in AS such as acute 
anterior uveitis and inﬂ  ammatory bowel disease. All three agents can be used as monotherapy 
and concomitant methotrexate appears to offer no advantages although insufﬁ  cient doses have 
been used to date. Future studies should target patients earlier in their disease course as well 
as those with adverse prognostic factors such as elevated serum metalloproteinase 3 levels and 
radiographic evidence of spinal ankylosis.
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Ankylosing spondylitis (AS) is a common inﬂ  ammatory joint disorder affecting the 
axial skeleton, peripheral large joints, certain entheses (attachments of tendons and 
ligaments to bone) and extra-articular sites such as the anterior uvea. It is increas-
ingly becoming more amenable to treatment, particularly since the introduction 
of anti-tumor necrosis factor alpha (anti-TNFα) therapies. Advances in therapy 
have been made possible by the availability and international standardization of 
clinical outcome measures and increasing recognition that magnetic resonance 
imaging (MRI) constitutes a valuable outcome tool for the objective evaluation 
of disease activity. The primary objectives in the management of AS are to reduce 
symptoms of pain and stiffness, to improve and/or maintain function and mobility, 
to prevent disability, to improve quality of life and to prevent structural damage. 
Over the past few years, there have been several notable advances in the use of 
both standard therapies for AS, such as non-steroidal anti-inﬂ  ammatory agents 
(NSAIDs), as well as the further development of anti-TNFα therapies, the latest 
agent introduced into clinical practice being adalimumab. Finally, several con-
sensus documents have been published outlining approaches to treatment in AS. Therapeutics and Clinical Risk Management 2007:3(6) 1126
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Nevertheless, several key issues remain to be resolved and 
these are highlighted later in this review.
Advances in the use of NSAIDs
Although these agents have been the cornerstone of phar-
macological intervention for AS since their introduction 
in the 1950s, there are still many questions that pertain to 
their appropriate use. Several NSAIDs are available with 
differences in chemical structure, dosage, pharmacology, 
half-life and adverse effects. It is not known if there are 
differences in efﬁ  cacy between NSAIDs, particularly when 
used in the long term, although it is generally accepted that 
aspirin is of limited efﬁ  cacy in AS. Their principal mode 
of action centers on the inhibition of cyclo-oxygenase, 
and NSAIDs vary in their ability to suppress expressed 
cyclo-oxygenase-1 (COX-1) versus the inducible form of 
the enzyme cyclo-oxygenase-2 (COX-2) which is highly 
regulated and increased in inﬂ  ammatory tissues. The latter 
is also constitutively expressed in the kidney, spleen and 
osteoblasts. Two recent studies suggest that there may be an 
advantage to using NSAIDs that are selective for COX-2, not 
only from the perspective of the suppression of inﬂ  ammation 
but also the prevention of structural damage progression. One 
study of a COX-2 selective, etoricoxib, recruited 387 patients 
that were randomized to etoricoxib 90 mg or 120 mg daily, 
naproxen 1,000 mg daily, or placebo, for 6-weeks followed 
by an extension phase to week 52 whereby placebo patients 
were randomly allocated to either naproxen or etoricoxib 
therapy (van der Heijde, Baraf, et al 2005). It is important 
to note that the dose of naproxen is that which is typically 
used by rheumatologists in the treatment of AS. More patients 
discontinued for lack of efﬁ  cacy in the placebo (47.3%) and 
naproxen (22.2%) groups than in those on etoricoxib (7.8% 
and 9.8% for the 90 mg and 120 mg groups, respectively). 
Discontinuation for adverse events was similar across groups. 
The primary end points were patient’s assessment of spinal 
pain (0–100 mm visual analogue scale (VAS)), patient’s 
global assessment of disease activity (0–100 mm VAS) and 
the Bath AS functional index (BASFI) (0–100 mm VAS). 
In addition to observing a statistically signiﬁ  cantly greater 
improvement in all 3 primary end points in the 90 mg and 
120 mg etoricoxib as compared to placebo treatment groups, 
the etoricoxib groups in combination also demonstrated sta-
tistically signiﬁ  cantly greater improvement when compared 
to naproxen for all 3 primary end points. The Assessments 
in AS International Working Group 20% response rates 
(ASAS 20) were 64.7%, 64.8%, 52.5%, and 20.4% in the 
90 mg etoricoxib, 120 mg etoricoxib, naproxen, and placebo 
groups, respectively. Maintenance of treatment effect was 
evaluated in the 6 to 52-week period of the study and this 
showed that both etoricoxib groups demonstrated signiﬁ  -
cantly greater effects compared with the naproxen group for 
all 3 primary end points with no loss of treatment effect over 
time. There were no signiﬁ  cant differences in the incidence of 
overall clinical adverse events, drug related clinical adverse 
events, laboratory adverse events, serious adverse events or 
discontinuations due to adverse events among all 4 treatment 
groups. However, 5 serious cardiovascular thrombotic events 
occurred in the extension phase and these were all noted in 
etoricoxib treated patients. Three patients receiving etori-
coxib and 4 receiving naproxen experienced peptic ulcer 
bleeds. To determine whether the differences between the 
etoricoxib and naproxen groups were clinically meaningful 
a 6-week comparison of the percentage of patients with a 
good to excellent response in each group was performed in 
a post-hoc analysis. The results corroborated those of the 
primary end points with signiﬁ  cantly more patients reporting 
a good to excellent response in the combined 90 and 120 mg 
etoricoxib treatment groups in comparison with the naproxen 
group. This, together with the differences in discontinuation 
rates and the ASAS 20 responses, generally supports the 
conclusion that treatment with etoricoxib is more efﬁ  cacious 
than treatment with either naproxen or placebo.
A recent active comparator trial of a second COX-2 
selective agent, celecoxib, is also of particular interest 
(Wanders et al 2005). This was a 2-year extension of a 
6-week randomized, double-blind, clinical trial that com-
pared celecoxib, ketoprofen, or placebo, with patients then 
being randomly allocated to receive either continuous treat-
ment with celecoxib at 100 mg twice daily or on- demand 
for a period of 2-years. Patients could increase this dosage 
to 200 mg twice daily or could switch to another NSAID 
while maintaining the same treatment strategy. The primary 
end point was structural damage progression measured over 
2-years using the modiﬁ  ed Stoke AS Spine Score (mSASSS) 
(Creemers et al 1994). This was evaluated by one observer 
who was blinded to the treatment strategy and temporal order 
of the radiographs. The primary objectives of the study were 
to determine whether continuous use of NSAIDs might be 
more effective in controlling the disease process leading to a 
reduction in structural damage progression. The study group 
comprised 215 patients, 111 of whom were randomized to 
continuous treatment and 104 to on-demand treatment. In the 
continuous treatment group, 96 completed the study, 68 on 
celecoxib and 28 taking a different NSAID. In the on-demand 
group, 86 completed the study, 67 on celecoxib and 19 on a Therapeutics and Clinical Risk Management 2007:3(6) 1127
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different NSAID. Withdrawal from treatment was therefore 
similar in both groups. Complete sets of radiographs were 
available for 76 patients on continuous treatment and 74 in 
the on-demand group. There were no statistically signiﬁ  cant 
differences in baseline characteristics of the 2 treatment 
groups although patients in the on-demand group had higher 
scores for global pain, spinal pain, night pain, patient global 
and baseline mSASSS radiograph damage score. The mean 
daily dose of celecoxib was 243 mg in the continuous treat-
ment group, and 201 mg in the on-demand group and this 
difference of 42 mg was statistically signiﬁ  cant. The prob-
ability plot for radiographic progression over 2-years showed 
that a greater proportion of patients in the on-demand group 
(45%) compared with the continuous treatment group (22%) 
demonstrated radiographic progression. In fact, the curve 
for radiographic progression in the on-demand group was 
to the left of the curve for the continuous treatment group 
along the entire range, reﬂ  ecting an overall higher level of 
radiographic progression. The mean score for progression at 
2-years was 0.4 mSASSS units in the continuous treatment 
group and 1.5 mSASSS units in the on-demand group, which 
was statistically signiﬁ  cant (p = 0.002). Disease activity 
was stable over time in both groups and although some-
what higher in the on-demand group, the differences were 
not statistically signiﬁ  cant. When analysis was conﬁ  ned to 
patients with a complete set of radiographs, time averaged 
values for pain at night and physician’s global assessment 
were signiﬁ  cantly worse in the on-demand treatment group. 
Regression analysis showed that differences in signs and 
symptoms at either baseline or during treatment could not 
explain the between-group differences in radiographic pro-
gression. There were no signiﬁ  cant differences in adverse 
events between the two groups.
The authors of this study concluded that the effects of 
NSAIDs on structural damage progression were indepen-
dent of their effects on disease activity but there are some 
potential pitfalls to their conclusions. Perhaps the most 
important relates to the differences in baseline character-
istics between the two groups. Although not signiﬁ  cantly 
different, the on-demand group had consistently higher 
parameters for disease severity measures, which included 
the mSASSS radiographic damage score. The latter is of par-
ticular relevance as baseline radiographic damage has been 
identiﬁ  ed as the only predictor of subsequent radiographic 
damage in a longitudinal analysis of AS patients (van der 
Heijde et al 2004). Consequently the differences between 
the two groups might reﬂ  ect inadequate randomization so 
that patients in the on-demand group had a more severe 
category of disease. Moreover, time averaged values for pain 
at night and physician’s global were also signiﬁ  cantly worse 
in the on-demand treatment group supporting the tenet that 
inadequate randomization may be a better explanation for 
the observed differences in primary outcome. On the other 
hand, there is biological plausibility for the study ﬁ  ndings 
in that COX-2 is constitutively expressed in osteoblasts and 
both COX-2 knock-out mice and mice treated with COX-2 
inhibiting drugs had reduced callous formation after a fracture 
(Zhang et al 2002). Moreover NSAIDs have been shown 
to reduce the risk of heterotopic bone formation after hip 
arthroplasty by 50 to 65% (Neal et al 2000).
These two studies raise the question as to whether there 
is a therapeutic advantage to the use of NSAIDs that are 
selective inhibitors of COX-2 in the management of patient 
with AS. Immunohistochemical analysis comparing synovial 
tissue samples obtained from patients with AS, osteoarthri-
tis (OA), rheumatoid arthritis (RA) and psoriatic arthritis 
showed the highest COX-2 expression in samples from 
patients with AS (Siegle et al 1998). This, together with a 
role for COX-2 in the process of ossiﬁ  cation, argues in favor 
of using these agents for the treatment of AS. On the other 
hand, COX-2 plays an important role in vascular homeostasis 
by sustaining vascular prostacyclin production and there is a 
concern that sustained COX-2 inhibition might increase the 
risk of vascular thrombosis. Moreover, many patients with 
AS maintain good symptomatic control with the use of an 
on-demand strategy and patients generally are reluctant to use 
medications continuously, particularly in view of the wide-
spread media exposure to the harmful effects of treatment 
with agents such as rofecoxib. A compromise proposal might 
be to recommend continuous NSAID therapy if radiography 
of the spine shows syndesmophytes and/or ankylosis but to 
use the lowest dose that controls the patient’s symptoms, eg, 
celecoxib 100 mg twice daily.
Second-line agents
The lack of efﬁ  cacy of second-line agents typically used in 
RA, including methotrexate, has been a major disappoint-
ment in AS. Two large randomized, multi-center, placebo-
controlled trials have shown that the efﬁ  cacy of salazopyrin 
is conﬁ  ned to those AS patients with concomitant peripheral 
arthritis (Dougados et al 1995; Clegg et al 1996). A recent 
systematic review of 11 trials with a total of 895 patients 
treated for period ranging from 12-weeks to 3-years show 
that differences between salazopyrin and placebo in a pooled 
analysis were statistically signiﬁ  cant only in erythrocyte 
sedimentation rates (ESR) and the severity of spinal stiffness Therapeutics and Clinical Risk Management 2007:3(6) 1128
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(Chen and Liu 2005). There was only one trial in which 
salazopyrin showed beneﬁ  t in primary outcome analyses 
that included back pain, chest expansion, occiput to wall 
test and patient global (Nissila et al 1988). In this trial, 
patients had the shortest disease duration and the highest 
level of ESR at baseline plus the greatest proportion with 
concomitant peripheral arthritis. There was, therefore, hope 
that this agent might be effective when used very early in 
the disease course. This was examined in a multi-center, 
randomized, placebo-controlled trial in which 230 patients 
were treated with either salazopyrin 1 gram twice a day or 
placebo for 24-weeks (Braun, Zochling et al 2006). Only 
patients with inﬂ  ammatory back pain (IBP) and features of 
spondyloarthritis according to the European Spondyloar-
thropathy Study Group (ESSG) classiﬁ  cation criteria were 
eligible for the study and patients could not have a symptom 
duration of more than 5-years. In addition to IBP, 47% of 
patients had peripheral arthritis and 50% had enthesitis at 
baseline. Only 13% showed radiographic changes fulﬁ  lling 
the modiﬁ  ed New York criteria for AS. The same number 
of patients (n = 17) withdrew from both treatment arms by 
24-weeks. There was no major difference in the primary 
outcome, the Bath AS disease activity index (BASDAI), 
between treatment groups although the median dose of 
NSAID was markedly lower in the salazopyrin group than 
in the placebo group (28 mg versus 88 mg diclofenac or 
equivalent/day). Subgroup analysis according to presence 
or absence of peripheral arthritis at baseline showed that in 
contrast to earlier studies patients with IBP but no peripheral 
arthritis treated with salazopyrin had a signiﬁ  cantly greater 
reduction in the BASDAI compared to those treated with 
placebo. There was no signiﬁ  cant difference in any outcome 
parameter between treatment groups in those patients with 
concomitant peripheral arthritis. This study, therefore, 
dispelled the hope that patients with early disease might be 
more responsive to salazopyrin therapy and also challenges 
current treatment recommendations that salazopyrin should 
be considered for those AS patients with concomitant periph-
eral arthritis (Braun, Baraliakos et al 2003; Maksymowych 
et al 2003). Further placebo-controlled trials of salazopyrin 
for AS are likely not warranted.
Anti-TNFα therapies
Anti-TNFα therapies represent a major advance in the treatment 
of AS (Table 1). Three agents are currently available, a chimeric 
monoclonal IgG1 antibody to TNFα, inﬂ  iximab, a recombinant 
75 kd TNFα receptor IgG1 fusion protein, etanercept, and a 
human monoclonal antibody to TNFα, adalimumab.
Etanercept
The ﬁ  rst pivotal phase III study of these agents in AS 
showed that etanercept was superior to placebo, signiﬁ  cant 
differences being apparent as soon as 2-weeks and ASAS 
20 responses being observed in 57% of etanercept treated 
patients as compared to 22% of those on placebo (Davis 
et al 2003). A substudy also revealed improvement in MRI 
features of spinal inﬂ  ammation although this was limited 
to evaluation of only the lower thoracic and lumbar spine 
(Baraliakos, Davis et al 2005). In the open-label phase, 
placebo patients switched to etanercept achieved similar 
responses to those seen in patients originally randomized 
to etanercept and prolonged follow up over 4-years has 
shown that the response to treatment is sustained (Davis, 
van der Heijde, Braun et al 2005). A recent report addresses 
the impact of etanercept on radiographic progression of 
structural damage in the spine over 2-years (van der Heijde, 
Landewe et al 2006). This is the minimum period of time 
required to demonstrate signiﬁ  cant change in a group of 
AS patients on standard therapies who might constitute a 
comparator group (Wanders et al 2004). Since anti-TNFα 
therapies have now been shown to be highly effective for 
the treatment of AS, it is ethically inappropriate to conduct 
2-year placebo-controlled trials that would be required 
to evaluate structural damage progression in randomly 
allocated treatment groups and a proposed solution has 
been the comparison of damage progression in patients 
on active therapy with a historical cohort of AS patients, 
particularly those who would otherwise meet the inclusion 
criteria for clinical trials of anti-TNFα therapies (van der 
Heijde, Landewe et al 2005). Such a comparison has shown 
no impact of etanercept on structural damage progression 
(van der Heijde, Landewe et al 2006). Deﬁ  nitive conclu-
sions should not be drawn because the historical cohort 
analyzed in this study was very different from patient 
cohorts recruited to trials of anti-TNFα therapy and simple 
comparisons based on subgroups stratiﬁ  ed by a limited 
number of inclusion criteria do not adequately address 
differences in disease characteristics between observational 
and clinical trial cohorts. It has been shown that physicians 
place equal or greater emphasis on disease characteristics 
other than those that typically constitute primary inclu-
sion criteria for clinical trials (eg, BASDAI greater than 
or equal to 4) (Pham et al 2006). Moreover, monoclonal 
anti-TNF antibodies have a different mechanism of action 
from etanercept and it would be erroneous to assume that 
ﬁ  ndings observed with the latter agent would necessarily 
also be observed with the former two agents.Therapeutics and Clinical Risk Management 2007:3(6) 1129
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Inﬂ  iximab
An earlier double-blind, placebo-controlled, randomized trial 
of inﬂ  iximab in 70 patients with AS conducted in Germany, 
established this agent as being efﬁ  cacious in the treatment of 
the signs and symptoms of AS (Braun et al 2002). A substudy 
of 20 patients who had MRI examination of the spine also 
showed improvement in spinal inﬂ  ammation (Braun, Pham 
et al 2003). Open-label follow up has demonstrated sustained 
responses over 3-years and withdrawal of treatment leads to 
disease relapse within 4-months in the majority of patients 
(Braun, Baraliakos, Brandt et al 2005; Baraliakos, Listing 
et al 2005). A pivotal phase III placebo-controlled study of 
inﬂ  iximab in AS recruited 279 patients of whom 201 received 
inﬂ  iximab 5 mg/kg at 0, 2 and 6-weeks, followed by every 
6-weeks thereafter for 2-years (van der Heijde, Dijkmans et al 
2005). Placebo patients received open-label inﬂ  iximab after 
24-weeks. An ASAS 20 response was observed in 61% of 
inﬂ  iximab patients as compared to 19% of placebo patients 
by 24-weeks. The signiﬁ  cant difference between treatment 
groups was evident as early as week 2. Treatment was well 
tolerated with similar proportions of serious adverse events, 
infusion reactions and serious infections between the two 
treatment groups. Patients in this trial also had MRI evalu-
ation conducted at baseline and 24-weeks. Patients in the 
inﬂ  iximab group had a signiﬁ  cantly greater improvement in 
spinal MRI activity score from baseline to week 24 than the 
patients in the placebo group (Braun, Landewe, et al 2006). 
The dose of inﬂ  iximab examined in most controlled and 
open-label studies of this agent in AS has been the same dose 
that was originally developed for the treatment of Crohn’s 
disease. A recent Canadian randomized, placebo-controlled 
trial has examined a dose of 3 mg/kg, using the same dosing 
regime that has been developed for the treatment of RA 
(Inman et al 2006). Preliminary ﬁ  ndings indicate a similar 
ASAS 20 response rate in the active treatment group.
Adalimumab
Several recent studies have focused on the evaluation of 
adalimumab in the treatment of AS. A preliminary open-label 
trial of adalimumab in AS recruited 14 patients refractory 
to NSAIDs who received 40 mg on alternate weeks over 
52-weeks (Haibhel et al 2006). An ASAS 20 response was 
seen in 70% of patients with 50% reporting a substantial 
response (ASAS 50). Signiﬁ  cant improvement was also 
noted in function, nocturnal pain and patient global. A further 
increase in the percentage of ASAS 20 responders to 86% 
was noted at week 20, after an increase in dosage to weekly 
therapy. This was accompanied by a reduction in sacroiliac 
joint and spinal inﬂ  ammation observed on MRI. A phase 
III pivotal, multi-center clinical trial of adalimumab 40 mg 
on alternate weeks in AS has now been reported (van der 
Heijde, Kivitz et al 2006). This trial recruited 315 patients 
with AS refractory to NSAIDs and second-line agents such 
as methotrexate and salazopyrin, of whom 208 were random-
ized to adalimumab 40 mg on alternate weeks and 107 to 
placebo for 24-weeks. After the week 12 assessment, patients 
not achieving an ASAS 20 response were eligible for early 
escape therapy with adalimumab. By week 24, only 27% 
of patients were still on placebo with the remainder having 
entered the early escape protocol and received open-label 
adalimumab. In contrast, only 39% of patients originally 
randomized to adalimumab entered the early escape protocol. 
A signiﬁ  cantly greater ASAS 20 response was observed in 
adalimumab treated patients (58.2%) as compared to those 
Table 1 Summary data for phase III pivotal trials of anti-TNFα therapies for AS
Study  Patient no  Disease  Primary endpoint  Primary endpoint  Secondary endpoints  Secondary endpoints
   duration    Active  Placebo      Active  Placebo
Davis et al  Etanercept = 138  10-years  ASAS 20 response  59%  28%  BASDAI    –40.6%  –7.6%
(2003) Placebo  = 139  10-years  at 12-weeks      ASAS 50    43%  8%
           CRP    –68.4%  –5%
Van der  Inﬂ  iximab = 201  8-years  ASAS 20 response  61.2%  19.2%  ASAS 40    47%  12%
Heijde et al  Placebo = 78  13-years  at 24-weeks      ASAS partial remission  22.4%  1.3%
2005          ASAS  5/6    49% 8.0%
           BASDAI    –43.9%  –6.2%
           BASFI    –29.8%  0%
Van der  Adalimumab = 208  11-years  ASAS 20 response  58.2%  20.6%  ASAS 40    39.9%  13.1%
Heijde et al  Placebo = 170  10-years  at 12-weeks      ASAS partial remission  20.7%  3.7%
2006          ASAS  5/6    48.6%  13.1%
           BASDAI    –41.3%  –12.7%
           BASFI    –68.8%  –14.3%Therapeutics and Clinical Risk Management 2007:3(6) 1130
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receiving placebo (20.6%) at week 12, the difference already 
being signiﬁ  cant by week 2. This is the only phase III trial 
that included patients with total spinal ankylosis and 50% 
(3 of 6) of the adalimumab treated patients achieved an 
ASAS 20 response at week 12 compared with 0% (0 of 5) 
of the placebo treated patients. Signiﬁ  cant improvement 
was also observed in measures of spinal mobility (Bath AS 
Metrology Index) and enthesitis (Maastricht AS enthesitis 
score (MASES)) at weeks 12 and 24. A highly signiﬁ  cant 
improvement was also observed in the acute phase reactant 
C-reactive protein and the physical and mental summary 
scores of the SF-36 Quality of Life instrument. The overall 
incidence of adverse events was signiﬁ  cantly higher in the 
adalimumab treated patients, although this was primarily due 
to an increased incidence of injection site reactions. There 
were no other statistically signiﬁ  cant differences in the inci-
dence of any other adverse events between treatment groups 
and no serious infections were reported in the adalimumab 
treated group. A smaller, randomized, placebo-controlled 
trial of adalimumab 40 mg on alternate weeks was con-
ducted in Canada and recruited 82 patients (Maksymowych, 
Rahman et al 2005). The design of the study was similar 
to the multinational trial in that it included an early escape 
option for patients failing to achieve an ASAS 20 response 
at week 12. Efﬁ  cacy at week 12 was similar to that observed 
in the multinational trial and comparable to that observed in 
trials of other anti-TNF agents. MRI evaluation was con-
ducted at baseline, 12 and 52-weeks and inﬂ  ammation was 
scored using the Spondyloarthritis Research Consortium of 
Canada (SPARCC) MRI index (Maksymowych et al 2005a, 
2005b; Lambert et al 2006). At week 12, decreases of 54% 
and 53% were noted in adalimumab treated patients for the 
spinal and sacroiliac joint SPARCC MRI scores, respectively, 
which were signiﬁ  cantly different from placebo (9.4% and 
12.7%, respectively). The response in adalimumab treated 
patients was maintained to 52-weeks and placebo patients 
switched to open label adalimumab treatment by week 24 
experienced similar reductions in spinal and sacroiliac joint 
inﬂ  ammation by week 52. Interestingly, similar large reduc-
tions in spinal and sacroiliac joint SPARCC scores were 
noted even in adalimumab-treated patients who were ASAS 
non-responders at 12-weeks.
Recent studies have examined the impact of anti-TNFα 
therapies on the extra-articular features of AS, particularly 
acute anterior uveitis (AAU). One study pooled data from 
both controlled and open-label studies of inﬂ  iximab and 
etanercept in AS (Braun, Baraliakos, Listing et al 2005). The 
incidence of AAU per 100 patient years was 15.6 in placebo 
patients as compared to 3.4 and 7.9 in inﬂ  iximab and etaner-
cept treated patients respectively. For all anti-TNFα treated 
patients, the incidence was 6.8 per 100 patient years. This sug-
gests that both inﬂ  iximab and etanercept might be effective 
in suppressing ﬂ  ares of uveitis. On the other hand, 2 recent 
observational studies indicate that etanercept does not appear 
to reduce ﬂ  ares of uveitis and, in fact, several patients have 
developed ﬂ  ares whilst on treatment (Cobo-Ibanez et al 
2006; Guignard et al 2006). In contrast, both inﬂ  iximab and 
adalimumab were shown to reduce ﬂ  ares of uveitis, suggest-
ing that monoclonal antibodies to anti-TNFα may be more 
effective in depressing ﬂ  ares of acute anterior uveitis. This is 
reminiscent of data observed from clinical trials of anti-TNF 
agents in agents with Crohn’s disease. Both inﬂ  iximab and 
adalimumab have been shown in pivotal phase III trials to 
ameliorate the activity in patients with Crohn’s disease whilst 
etanercept has proven to be ineffective (Sandborn et al 1997; 
Targen et al 1997; Hanauer et al 2006). In fact, studies have 
reported ﬂ  ares of Crohn’s and other granulomatous disorders 
in patients whose spondylitis responded to treatment with 
etanercept (Oh et al 2005; Gonzalez-Lopez et al 2006). 
Additional data in both pulmonary and ocular sarcoidosis 
also attests to the efﬁ  cacy of inﬂ  iximab in the treatment of 
granulomatous inﬂ  ammation in contrast to etanercept (Utz 
et al 2003; Baughman et al 2005, 2006).
In conclusion, all three available anti-TNFα agents appear 
to have similar efﬁ  cacy for the articular manifestations of AS 
with clinical responses being observed in 60% of patients. 
There is mounting evidence that the two available mono-
clonal antibodies, inﬂ  iximab and adalimumab, are superior 
in treating extra-articular features such as AAU and inﬂ  am-
matory bowel disease. There is no evidence at this time that 
any anti-TNFα agent is disease modifying with respect to 
prevention of structural damage progression and one study 
evaluating etanercept in fact showed no effect. Because 40% 
of AS patients do not respond to anti-TNFα therapies, it has 
been suggested that the addition of methotrexate might be 
beneﬁ  cial by analogy with the considerable improvement 
in efﬁ  cacy consistently observed with all three anti-TNFα 
agents in trials of RA. One study of 123 AS patients examined 
the combination of methotrexate 12.5 mg weekly in addition 
to inﬂ  iximab 5 mg/kg over 54-weeks (Breban et al 2005). 
However, there was no treatment group difference in ASAS 
20 response rate.
Safety of anti-TNFα agents
Long term observational studies of anti-TNF agents are 
currently being conducted internationally and in general, Therapeutics and Clinical Risk Management 2007:3(6) 1131
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afﬁ  rm that these agents are well tolerated in real world 
practice. A pooled analysis of data from placebo-controlled 
trials of anti-TNF agents in RA has demonstrated a dose 
dependent increase in the rate of malignancy (Bongartz et al 
2006). However, this has not been shown in most longitudinal 
cohorts of patients receiving these drugs in real world prac-
tice (Askling, Fored, Baecklund et al 2005; Askling, Fored, 
Brandt et al 2005; Askling et al 2006; Setoguchi et al 2006). 
An increased rate of serious infection has been reported in 
RA patients receiving anti-TNF therapies in Germany but 
not in the UK (Listing et al 2005; Dixon et al 2006). A major 
recent development is a recognition that chronic inﬂ  ammatory 
disorders such as RA and AS are strongly associated with 
increased rates of cardiovascular events and that prolonged 
therapy with anti-TNF agents may reduce the frequency of 
these events and thereby improve life expectancy (Jacobsson 
et al 2005).
Current controversies and future 
directions
A major resolve question is whether anti-TNF therapies are 
disease modifying with respect to prevention of structural 
damage progression. One study conducted with etanercept 
suggests a lack of impact (van der Heijde, Baraf et al 2005). 
Data from studies with inﬂ  iximab and adalimumab are 
currently awaited. However, even if this data shows a lack 
of impact, it is important to note that patients recruited to 
phase III trials of these agents typically have a long disease 
duration, the mean duration from time of diagnosis typi-
cally being greater than 10-years. It is therefore important 
to conduct further trials in patients presenting much earlier 
in their disease course. Resolving the question of disease 
modiﬁ  cation is important because cost/beneﬁ  t consider-
ations have assumed increasing importance and anti-TNFα 
therapies are still not available in many parts of the world 
for the treatment of AS. Cost/beneﬁ  t calculations could also 
be rendered more attractive if reliable predictors of response 
could be established. Preliminary data points to baseline 
disease activity, baseline function, CRP and MRI features of 
inﬂ  ammation as potential predictors (Rudwaleit et al 2004; 
Davis, van der Heijde, Dougados et al 2005). Recent studies 
have also shown that anti-TNFα therapies are associated with 
signiﬁ  cant changes in certain biomarkers but none have yet 
been shown to predict response to treatment (Maksymowych, 
Patra et al 2005; Maksymowych, Poole et al 2005). Further 
studies of the disease modifying potential of anti-TNFα 
agents in AS could be rendered more attractive if it were 
possible to identify a sub-group of patients at much greater 
risk of structural damage progression. This now appears to be 
possible as a recent study has demonstrated that a combina-
tion of an elevated serum metalloproteinase-3 level together 
with evidence of pre-existing damage on spinal x-rays is a 
signiﬁ  cant predictor of further damage developing over the 
course of 2-years (Maksymowych et al 2006). This subgroup 
of patients should therefore be targeted in future clinical tri-
als assessing the disease modifying properties of new and 
existing therapies. Combination therapy for AS is an issue 
that requires further evaluation. In current clinical practice, 
many patients who achieve good responses to anti-TNFα 
therapy discontinue their concomitant NSAID therapy. This 
may be unwise if further studies show that NSAID therapy, 
and COX-2 selective agents in particular, prevent the devel-
opment of spinal ossiﬁ  cation. Only one study has evaluated 
concomitant therapy with methotrexate and this study used 
doses of methotrexate that many rheumatologists would 
consider inadequate (Breban et al 2005). Further studies 
should clarify once and for all if methotrexate is efﬁ  cacious 
in combination with anti-TNFα therapies.
The past decade has witnessed breathtaking advances in 
the treatment of AS. There is every reason to believe that the 
pace of advances will accelerate over the ensuing decade.
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